Literature DB >> 16087902

Effect of reproductive factors and postmenopausal hormone use on the risk of Parkinson disease.

R A Popat1, S K Van Den Eeden, C M Tanner, V McGuire, A L Bernstein, D A Bloch, A Leimpeter, L M Nelson.   

Abstract

OBJECTIVE: Parkinson disease (PD) is less common in women possibly because of hormonal or reproductive influences. The objective of this study was to evaluate the associations of reproductive factors and postmenopausal hormone use with the risk of PD among postmenopausal women.
METHODS: Incident cases (n = 178) and randomly selected age-matched controls (n = 189) who were members of the Kaiser Permanente Medical Care Program (KPMCP) of Northern California participated in the study conducted during the years 1994 to 1995. Statistical analyses were carried out using logistic regression.
RESULTS: The association of postmenopausal hormone use with PD risk depended on the type of menopause. Among women with history of a hysterectomy with or without an oophorectomy, estrogen use alone was associated with a 2.6-fold increased risk (adjusted odds ratio (OR) 2.6, 95% CI: 1.1 to 6.1) and significant trends in the risk of PD were observed with increasing duration of estrogen use, but disease risk was not influenced by recency of use. In contrast, among women with natural menopause, no increased risk of PD was observed with hormone use (estrogen alone or a combined estrogen-progestin regimen). Early age at final menstrual period (44 years or younger) was associated with reduction in risk (adjusted OR 0.5, 95% CI: 0.3 to 1.0). Age at menarche and parity were not associated with the risk of PD.
CONCLUSION: Postmenopausal use of estrogen alone may increase the risk of Parkinson disease (PD) among women with a hysterectomy. Among women with natural menopause for whom the usual treatment is combined estrogen-progestin therapy, no increased risk of PD was observed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16087902     DOI: 10.1212/01.wnl.0000171344.87802.94

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  35 in total

Review 1.  Parkinson's disease in women: a call for improved clinical studies and for comparative effectiveness research.

Authors:  J M Pavon; H E Whitson; M S Okun
Journal:  Maturitas       Date:  2010-02-01       Impact factor: 4.342

2.  Reproductive factors, exogenous estrogen use, and risk of Parkinson's disease.

Authors:  Kelly Claire Simon; Honglei Chen; Xiang Gao; Michael A Schwarzschild; Alberto Ascherio
Journal:  Mov Disord       Date:  2009-07-15       Impact factor: 10.338

Review 3.  Genetics of iron regulation and the possible role of iron in Parkinson's disease.

Authors:  Shannon L Rhodes; Beate Ritz
Journal:  Neurobiol Dis       Date:  2008-07-11       Impact factor: 5.996

4.  The complexities of hormonal influences and risk of Parkinson's disease.

Authors:  Connie Marras; Rachel Saunders-Pullman
Journal:  Mov Disord       Date:  2014-04-30       Impact factor: 10.338

5.  Formulations of hormone therapy and risk of Parkinson's disease.

Authors:  Jessica I Lundin; Thanh G N Ton; Andrea Z LaCroix; W T Longstreth; Gary M Franklin; Phillip D Swanson; Terri Smith-Weller; Brad A Racette; Harvey Checkoway
Journal:  Mov Disord       Date:  2014-09-25       Impact factor: 10.338

Review 6.  Sex-related differences in oxidative stress and neurodegeneration.

Authors:  Mavis A Tenkorang; Brina Snyder; Rebecca L Cunningham
Journal:  Steroids       Date:  2017-12-20       Impact factor: 2.668

7.  Female reproductive factors, menopausal hormone use, and Parkinson's disease.

Authors:  Rui Liu; Donna Baird; Yikyung Park; Neal D Freedman; Xuemei Huang; Albert Hollenbeck; Aaron Blair; Honglei Chen
Journal:  Mov Disord       Date:  2013-12-18       Impact factor: 10.338

8.  Lifetime exposure to estrogen and progressive supranuclear palsy: Environmental and Genetic PSP study.

Authors:  Hee Kyung Park; Sindana Ilango; Christina M Charriez; Harvey Checkoway; David Riley; David G Standaert; Yvette Bordelon; David R Shprecher; Stephen G Reich; Deborah Hall; Benzi Kluger; Connie Marras; Joseph Jankovic; Richard Dubinsky; Irene Litvan
Journal:  Mov Disord       Date:  2018-02-20       Impact factor: 10.338

9.  Brain angiotensin and dopaminergic degeneration: relevance to Parkinson's disease.

Authors:  Jose L Labandeira-Garcia; Jannette Rodriguez-Pallares; Ana I Rodríguez-Perez; Pablo Garrido-Gil; Begoña Villar-Cheda; Rita Valenzuela; Maria J Guerra
Journal:  Am J Neurodegener Dis       Date:  2012-11-18

10.  Risk of Parkinson's disease after tamoxifen treatment.

Authors:  Jeanne C Latourelle; Merete Dybdahl; Anita L Destefano; Richard H Myers; Timothy L Lash
Journal:  BMC Neurol       Date:  2010-04-12       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.